Competition Coming for Myriad's BRCA Test, Whether or Not Gene Patents Hold Up | GenomeWeb

NEW YORK (GenomeWeb News) – In the next few years, or perhaps even sooner, Myriad may be at risk of losing its grip over the lucrative BRCA testing franchise in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.